Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyCellularComponent	chromatin	KMT2E BAZ2A INO80D NEUROD4 SCML2 NPAS2 KANSL1	5.82e-04	1480	22	7	GO:0000785
GeneOntologyCellularComponent	postsynaptic specialization	CDKL5 NRG1 SIPA1L1 CHRNB2	1.72e-03	503	22	4	GO:0099572
GeneOntologyCellularComponent	nuclear protein-containing complex	KMT2E BAZ2A INO80D SCML2 NPAS2 KANSL1	2.41e-03	1377	22	6	GO:0140513
Domain	PHD	KMT2E BAZ2A	3.18e-03	75	21	2	PF00628
Domain	Znf_PHD-finger	KMT2E BAZ2A	3.52e-03	79	21	2	IPR019787
Domain	PHD	KMT2E BAZ2A	4.45e-03	89	21	2	SM00249
Domain	Znf_PHD	KMT2E BAZ2A	4.64e-03	91	21	2	IPR001965
Domain	ZF_PHD_2	KMT2E BAZ2A	5.05e-03	95	21	2	PS50016
Domain	ZF_PHD_1	KMT2E BAZ2A	5.15e-03	96	21	2	PS01359
Domain	-	NEUROD4 NPAS2	6.59e-03	109	21	2	4.10.280.10
Domain	HLH	NEUROD4 NPAS2	6.83e-03	111	21	2	PF00010
Domain	HLH	NEUROD4 NPAS2	7.43e-03	116	21	2	SM00353
Domain	BHLH	NEUROD4 NPAS2	7.56e-03	117	21	2	PS50888
Domain	bHLH_dom	NEUROD4 NPAS2	7.68e-03	118	21	2	IPR011598
Domain	Znf_FYVE_PHD	KMT2E BAZ2A	1.17e-02	147	21	2	IPR011011
Pubmed	A fate-mapping approach reveals the composite origin of the connecting tubule and alerts on "single-cell"-specific KO model of the distal nephron.	SLC4A1 SLC12A3	3.82e-06	5	22	2	27582101
Pubmed	Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney.	SLC4A1 SLC12A3	5.72e-06	6	22	2	12388412
Pubmed	The European renal genome project: an integrated approach towards understanding the genetics of kidney development and disease.	CHRNB2 SLC4A1 NPAS2 SLC12A3	9.01e-06	212	22	4	19521566
Pubmed	ErbB4 modulates tubular cell polarity and lumen diameter during kidney development.	NRG1 SLC12A3	1.71e-05	10	22	2	22076439
Pubmed	Generation of Distal Renal Segments Involves a Unique Population of Aqp2 + Progenitor Cells.	SLC4A1 SLC12A3	6.49e-05	19	22	2	34667084
Pubmed	Inactivation of Notch signaling in the renal collecting duct causes nephrogenic diabetes insipidus in mice.	SLC4A1 SLC12A3	7.96e-05	21	22	2	19855135
Pubmed	Grainyhead-related transcription factor is required for duct maturation in the salivary gland and the kidney of the mouse.	SLC4A1 SLC12A3	1.05e-04	24	22	2	17079272
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	PCNX3 BAZ2A INO80D ESYT1 SIPA1L1 SCML2	2.59e-04	1497	22	6	31527615
Pubmed	Single-cell transcriptomics of the early developing mouse cerebral cortex disentangle the spatial and temporal components of neuronal fate acquisition.	NRG1 NEUROD4	5.76e-04	56	22	2	34170322
Cytoband	Xp22	CDKL5 SCML2	6.53e-05	25	22	2	Xp22
Cytoband	12q13.2	NEUROD4 ESYT1	3.21e-04	55	22	2	12q13.2
Cytoband	17q21.31	SLC4A1 KANSL1	7.11e-04	82	22	2	17q21.31
Cytoband	Ensembl 112 genes in cytogenetic band chr12q13	BAZ2A NEUROD4 ESYT1	1.05e-03	423	22	3	chr12q13
Cytoband	Ensembl 112 genes in cytogenetic band chr7q22	KMT2E MUC12	4.91e-03	219	22	2	chr7q22
Cytoband	Ensembl 112 genes in cytogenetic band chrXp22	CDKL5 SCML2	6.35e-03	250	22	2	chrXp22
Cytoband	Ensembl 112 genes in cytogenetic band chr11q13	PCNX3 CATSPER1	1.98e-02	454	22	2	chr11q13
Cytoband	Ensembl 112 genes in cytogenetic band chr17q21	SLC4A1 KANSL1	2.14e-02	473	22	2	chr17q21
GeneFamily	PHD finger proteins	KMT2E BAZ2A	3.56e-03	90	18	2	88
GeneFamily	Basic helix-loop-helix proteins	NEUROD4 NPAS2	5.27e-03	110	18	2	420
Computational	Neighborhood of BNIP3L	SLC4A1 SLC12A3	2.94e-03	68	13	2	GNF2_BNIP3L
Computational	Neighborhood of RAD23A	SLC4A1 SLC12A3	3.03e-03	69	13	2	GNF2_RAD23A
Computational	Neighborhood of TAL1	SLC4A1 SLC12A3	3.38e-03	73	13	2	GNF2_TAL1
Computational	Neighborhood of ANK1	SLC4A1 SLC12A3	3.47e-03	74	13	2	GNF2_ANK1
Computational	Neighborhood of SPTB	SLC4A1 SLC12A3	3.47e-03	74	13	2	GNF2_SPTB
Computational	Neighborhood of MAP2K3	SLC4A1 SLC12A3	3.57e-03	75	13	2	GNF2_MAP2K3
Computational	NCI cell lines expression clusters.	NRG1 MAN2A2	4.05e-03	80	13	2	MODULE_213
Computational	Neighborhood of SPTA1	SLC4A1 SLC12A3	4.15e-03	81	13	2	GNF2_SPTA1
Drug	Brompheniramine maleate [980-71-2]; Up 200; 9.2uM; MCF7; HT_HG-U133A	INO80D NEUROD4 SCML2 MAN2A2	3.02e-05	199	21	4	3271_UP
Drug	Aztreonam [78110-38-0]; Up 200; 9.2uM; MCF7; HT_HG-U133A	BAZ2A INO80D SCML2 MAN2A2	3.08e-05	200	21	4	5535_UP
Drug	magnesium oxide	BAZ2A SLC12A3	2.03e-04	23	21	2	CID000014792
Drug	l-Lobeline	CHRNB2 SLC4A1	4.47e-04	34	21	2	CID000003945
Drug	Bisacodyl [603-50-9]; Up 200; 11uM; MCF7; HT_HG-U133A	BAZ2A NEUROD4 NPAS2	6.11e-04	183	21	3	5677_UP
Drug	Azacytidine-5 [320-67-2]; Up 200; 16.4uM; PC3; HT_HG-U133A	BAZ2A NRG1 SLC4A1	6.60e-04	188	21	3	4010_UP
Drug	Niflumic Acid	CHRNB2 SLC4A1	6.82e-04	42	21	2	ctd:D009544
Drug	Metanephrine hydrochloride DL [881-95-8]; Up 200; 17.2uM; PC3; HT_HG-U133A	NRG1 CHRNB2 MAN2A2	7.02e-04	192	21	3	6734_UP
Drug	Chlorhexidine [55-56-1]; Up 200; 8uM; MCF7; HT_HG-U133A	BAZ2A INO80D CHRNB2	7.02e-04	192	21	3	1525_UP
Drug	prochlorperazine dimaleate salt; Up 200; 10uM; MCF7; HG-U133A	BAZ2A SCML2 MAN2A2	7.13e-04	193	21	3	455_UP
Drug	Fusaric acid [536-69-6]; Up 200; 22.4uM; MCF7; HT_HG-U133A	BAZ2A INO80D NRG1	7.23e-04	194	21	3	3245_UP
Drug	Altretamine [654-05-6]; Down 200; 19uM; MCF7; HT_HG-U133A	BAZ2A INO80D SIPA1L1	7.23e-04	194	21	3	6467_DN
Drug	Sulfameter [651-06-9]; Down 200; 14.2uM; PC3; HT_HG-U133A	BAZ2A SCML2 NPAS2	7.23e-04	194	21	3	5732_DN
Drug	Phenazopyridine hydrochloride [136-40-3]; Down 200; 16uM; MCF7; HT_HG-U133A	INO80D SIPA1L1 SCML2	7.34e-04	195	21	3	6234_DN
Drug	sodium 4-phenylbutyrate; Down 200; 1000uM; PC3; HG-U133A	SIPA1L1 CHRNB2 NPAS2	7.34e-04	195	21	3	434_DN
Drug	estradiol, USP; Up 200; 0.1uM; HL60; HT_HG-U133A	BAZ2A INO80D SIPA1L1	7.34e-04	195	21	3	2668_UP
Drug	Mefexamide hydrochloride [3413-64-7]; Up 200; 12.6uM; PC3; HT_HG-U133A	BAZ2A INO80D SCML2	7.34e-04	195	21	3	2121_UP
Drug	Trimeprazine tartrate [4330-99-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A	INO80D SIPA1L1 MAN2A2	7.34e-04	195	21	3	3478_UP
Drug	Tracazolate hydrochloride [41094-88-6]; Down 200; 11.8uM; PC3; HT_HG-U133A	BAZ2A INO80D NPAS2	7.45e-04	196	21	3	6619_DN
Drug	Minoxidil [38304-91-5]; Down 200; 19.2uM; HL60; HG-U133A	INO80D CHRNB2 MAN2A2	7.45e-04	196	21	3	1996_DN
Drug	Proadifen hydrochloride [62-68-0]; Up 200; 10.2uM; PC3; HT_HG-U133A	BAZ2A SCML2 MAN2A2	7.45e-04	196	21	3	5807_UP
Drug	Nalbuphine hydrochloride [23277-43-2]; Down 200; 10.2uM; HL60; HG-U133A	BAZ2A INO80D CHRNB2	7.45e-04	196	21	3	1379_DN
Drug	Piperine [94-62-2]; Up 200; 14uM; MCF7; HT_HG-U133A	BAZ2A CHRNB2 MAN2A2	7.45e-04	196	21	3	3263_UP
Drug	Spironolactone [52-01-7]; Up 200; 9.6uM; PC3; HT_HG-U133A	BAZ2A CHRNB2 MAN2A2	7.45e-04	196	21	3	5781_UP
Drug	Levopropoxyphene napsylate [5714-90-9]; Down 200; 7.4uM; HL60; HT_HG-U133A	BAZ2A SIPA1L1 SCML2	7.56e-04	197	21	3	2980_DN
Drug	novobiocin sodium, USP; Down 200; 100uM; PC3; HG-U133A	BAZ2A CHRNB2 NPAS2	7.56e-04	197	21	3	435_DN
Drug	Bupropion hydrochloride [31677-93-7]; Up 200; 14.4uM; HL60; HG-U133A	BAZ2A ESYT1 CHRNB2	7.56e-04	197	21	3	1564_UP
Drug	alpha-Santonin [481-06-1]; Up 200; 16.2uM; MCF7; HT_HG-U133A	NEUROD4 CHRNB2 NPAS2	7.56e-04	197	21	3	3877_UP
Drug	Hexetidine [141-94-6]; Down 200; 11.8uM; HL60; HT_HG-U133A	INO80D NEUROD4 CHRNB2	7.56e-04	197	21	3	2457_DN
Drug	Vancomycin hydrochloride [1404-93-9]; Up 200; 2.6uM; MCF7; HT_HG-U133A	NEUROD4 CHRNB2 NPAS2	7.56e-04	197	21	3	2858_UP
Drug	Picotamide monohydrate [80530-63-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A	NEUROD4 SIPA1L1 SCML2	7.56e-04	197	21	3	2233_DN
Drug	Vincamine [1617-90-9]; Up 200; 11.2uM; MCF7; HT_HG-U133A	BAZ2A INO80D NEUROD4	7.56e-04	197	21	3	2327_UP
Drug	Methylhydantoin-5-(D) [55147-68-7]; Down 200; 35uM; HL60; HT_HG-U133A	INO80D NRG1 SIPA1L1	7.56e-04	197	21	3	2994_DN
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; MCF7; HT_HG-U133A	BAZ2A INO80D SCML2	7.56e-04	197	21	3	4832_DN
Drug	Pivampicillin [33817-20-8]; Up 200; 8.6uM; PC3; HT_HG-U133A	BAZ2A NEUROD4 CHRNB2	7.56e-04	197	21	3	5046_UP
Drug	Esculin Hydrate [531-75-9]; Up 200; 11.8uM; PC3; HT_HG-U133A	BAZ2A INO80D MAN2A2	7.56e-04	197	21	3	6310_UP
Drug	Cefoxitin sodium salt [33564-30-6]; Up 200; 8.8uM; MCF7; HT_HG-U133A	NEUROD4 SIPA1L1 MAN2A2	7.56e-04	197	21	3	6796_UP
Drug	Letrozole [112809-51-5]; Up 200; 14uM; PC3; HT_HG-U133A	BAZ2A INO80D MAN2A2	7.56e-04	197	21	3	4240_UP
Drug	Arcaine sulfate [14923-17-2]; Down 200; 14.8uM; PC3; HT_HG-U133A	BAZ2A INO80D NPAS2	7.56e-04	197	21	3	6629_DN
Drug	Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; MCF7; HT_HG-U133A	INO80D NEUROD4 CHRNB2	7.56e-04	197	21	3	6061_DN
Drug	ICI 182,780; Up 200; 1uM; HL60; HT_HG-U133A	BAZ2A SIPA1L1 CHRNB2	7.56e-04	197	21	3	2665_UP
Drug	Selegiline hydrochloride [14611-52-0]; Up 200; 17.8uM; MCF7; HT_HG-U133A	BAZ2A NEUROD4 SIPA1L1	7.56e-04	197	21	3	2826_UP
Drug	Cefixime [79350-37-1]; Up 200; 8.8uM; MCF7; HT_HG-U133A	BAZ2A CHRNB2 MAN2A2	7.56e-04	197	21	3	3247_UP
Drug	Nifuroxazide [965-52-6]; Up 200; 14.6uM; HL60; HT_HG-U133A	NRG1 NEUROD4 SLC12A3	7.56e-04	197	21	3	2490_UP
Drug	Rolipram [61413-54-5]; Up 200; 14.6uM; MCF7; HT_HG-U133A	NEUROD4 CHRNB2 MAN2A2	7.56e-04	197	21	3	6449_UP
Drug	Hecogenin [467-55-0]; Up 200; 9.2uM; HL60; HT_HG-U133A	BAZ2A NPAS2 SLC12A3	7.68e-04	198	21	3	2716_UP
Drug	Isradipine [75695-93-1]; Up 200; 10.8uM; MCF7; HT_HG-U133A	BAZ2A INO80D MAN2A2	7.68e-04	198	21	3	6508_UP
Drug	Nystatine [1400-61-9]; Down 200; 4.4uM; HL60; HT_HG-U133A	BAZ2A INO80D SIPA1L1	7.68e-04	198	21	3	2500_DN
Drug	Amoxapine [14028-44-5]; Down 200; 12.8uM; HL60; HG-U133A	BAZ2A INO80D MAN2A2	7.68e-04	198	21	3	2013_DN
Drug	Cyclacillin [3485-14-1]; Up 200; 11.8uM; MCF7; HT_HG-U133A	NEUROD4 MAN2A2 SLC12A3	7.68e-04	198	21	3	4358_UP
Drug	Baclofen (R,S) [1134-47-0]; Down 200; 18.8uM; MCF7; HT_HG-U133A	BAZ2A INO80D SIPA1L1	7.68e-04	198	21	3	5414_DN
Drug	Ticlopidine hydrochloride [53885-35-1]; Up 200; 13.4uM; PC3; HT_HG-U133A	BAZ2A NRG1 MAN2A2	7.68e-04	198	21	3	4074_UP
Drug	Avermectin B1 [71751-41-2]; Down 200; 4.8uM; PC3; HT_HG-U133A	BAZ2A SIPA1L1 NPAS2	7.68e-04	198	21	3	5864_DN
Drug	Scoulerine [6451-73-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A	BAZ2A INO80D NEUROD4	7.68e-04	198	21	3	2891_UP
Drug	Deferoxamine mesylate [138-14-7]; Up 200; 6uM; MCF7; HT_HG-U133A	BAZ2A NEUROD4 NPAS2	7.68e-04	198	21	3	3417_UP
Drug	Zuclopenthixol hydrochloride [633-59-0]; Down 200; 9.2uM; MCF7; HT_HG-U133A	INO80D NEUROD4 SCML2	7.79e-04	199	21	3	4843_DN
Drug	Mefenamic acid [61-68-7]; Up 200; 16.6uM; MCF7; HT_HG-U133A	BAZ2A SIPA1L1 MAN2A2	7.79e-04	199	21	3	5534_UP
Drug	Methyldopa (L,-) [555-30-6]; Down 200; 19uM; MCF7; HT_HG-U133A	INO80D NEUROD4 CHRNB2	7.79e-04	199	21	3	5637_DN
Drug	Flurbiprofen [5104-49-4]; Up 200; 16.4uM; MCF7; HT_HG-U133A	BAZ2A INO80D CHRNB2	7.79e-04	199	21	3	5269_UP
Drug	(-)-MK 801 hydrogen maleate [77086-19-2]; Down 200; 11.8uM; MCF7; HT_HG-U133A	BAZ2A INO80D SCML2	7.79e-04	199	21	3	6458_DN
Drug	Metampicillin sodium salt [6489-61-8]; Up 200; 10.4uM; MCF7; HT_HG-U133A	BAZ2A INO80D SCML2	7.79e-04	199	21	3	5540_UP
Drug	Methiothepin maleate [19728-88-2]; Up 200; 8.4uM; PC3; HT_HG-U133A	BAZ2A INO80D NPAS2	7.79e-04	199	21	3	6312_UP
Drug	Oxytetracycline dihydrate [6153-64-6]; Up 200; 8uM; PC3; HT_HG-U133A	BAZ2A SLC4A1 MAN2A2	7.79e-04	199	21	3	5772_UP
Drug	Biperiden hydrochloride [1235-82-1]; Down 200; 11.4uM; MCF7; HT_HG-U133A	BAZ2A INO80D SCML2	7.79e-04	199	21	3	5644_DN
Drug	Nomifensine maleate [32795-47-4]; Up 200; 11.2uM; MCF7; HT_HG-U133A	BAZ2A MAN2A2 SLC12A3	7.90e-04	200	21	3	2224_UP
Drug	Fluorometholone [426-13-1]; Down 200; 10.6uM; MCF7; HT_HG-U133A	INO80D NEUROD4 SIPA1L1	7.90e-04	200	21	3	6071_DN
Drug	Rolipram [61413-54-5]; Down 200; 14.6uM; MCF7; HT_HG-U133A	INO80D SIPA1L1 SCML2	7.90e-04	200	21	3	6449_DN
Drug	Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; HL60; HT_HG-U133A	SIPA1L1 SCML2 SLC12A3	7.90e-04	200	21	3	2169_UP
Disease	Renal tubular acidosis	SLC4A1 SLC12A3	3.18e-06	4	22	2	C0001126
Disease	Nephritis, Tubulointerstitial	SLC4A1 SLC12A3	1.10e-04	21	22	2	C0041349
Disease	Nephritis, Interstitial	SLC4A1 SLC12A3	1.45e-04	24	22	2	C0027707
Disease	Autistic Disorder	KMT2E CHRNB2 NPAS2	9.30e-04	261	22	3	C0004352
Disease	schizophrenia (implicated_via_orthology)	NRG1 MAN2A2	1.17e-03	68	22	2	DOID:5419 (implicated_via_orthology)
Disease	QRS duration	NRG1 SIPA1L1 NPAS2	1.36e-03	298	22	3	EFO_0005055
Disease	household income	KMT2E NPAS2 KANSL1	1.44e-03	304	22	3	EFO_0009695
Disease	Neurodevelopmental Disorders	KMT2E CDKL5	2.18e-03	93	22	2	C1535926
Disease	cerebrospinal fluid biomarker measurement	NRG1 CATSPER1	2.32e-03	96	22	2	EFO_0006794
Disease	QRS-T angle	SIPA1L1 KANSL1	2.82e-03	106	22	2	EFO_0020097

Protein segments in the cluster

Peptide	Gene	Start	Entry
EAHSHSYSHSSSSLS	ESYT1	921	Q9BSJ8
PYSESFHHSEASHLS	CATSPER1	186	Q8NEC5
ATATDYHTTSHPGTH	SLC4A1	41	P02730
SSSTSHLHHPSVAYD	BAZ2A	76	Q9UIF9
SFSTSHYTSTAHHST	NRG1	331	Q02297
HSPSASSRSSHKSSH	NPAS2	406	Q99743
DRHSHSSSFHSADVP	PCNX3	701	Q9H6A9
SSSSYLAATHHPPHS	KANSL1	806	Q7Z3B3
SPDVSSSHSLSEYSH	KANSL1	971	Q7Z3B3
YPHQLYTSSSHHSHS	KMT2E	41	Q8IZD2
YTSSSHHSHSYIGLP	KMT2E	46	Q8IZD2
ESVHQSHSYSSSHSN	OTOP2	191	Q7RTS6
PTDSSHYFSCSHSSS	DUXB	191	A0A1W2PPF3
DSHSTSYPSLLSHLT	MAN2A2	1001	P49641
YSSDHSHSSPHGSHY	INO80D	816	Q53TQ3
HSHSLSAPHESFSYG	CDKL5	581	O76039
HSDSHYSSHSSSNTL	SIPA1L1	1276	O43166
YTTTTFLHSDHSAPS	CHRNB2	486	P17787
HFAVSASLSSHSSHL	ZNF804B	1216	A4D1E1
PFSSSRGHTHSSAEH	SCML2	466	Q9UQR0
AYDSSHPSHLTHSST	SLC12A3	36	P55017
FSDSSSLTPHHRTHS	ZNF483	476	Q8TF39
TSYHSSPGSTATTHF	MUC12	1966	Q9UKN1
TSYHSSPGSTATTHF	MUC12	4606	Q9UKN1
PHYPSSSLSSGHVHS	NEUROD4	281	Q9HD90